Compare BYAH & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYAH | XAIR |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | China | United States |
| Employees | 40 | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.4M |
| IPO Year | N/A | 2015 |
| Metric | BYAH | XAIR |
|---|---|---|
| Price | $0.84 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 4.3M | 254.0K |
| Earning Date | 03-02-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,679,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.05 | $0.33 |
| 52 Week High | $6.49 | $3.78 |
| Indicator | BYAH | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 52.66 |
| Support Level | $0.14 | $0.44 |
| Resistance Level | $1.45 | $0.51 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 1.06 | 65.88 |
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.